ArticleArchives of gynecology and obstetrics2025
Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGonadotropin-releasing hormone (GnRH) receptor antagonists in combination therapy offer a promising advancement in the medical management of uterine fibroids. While effective for symptom control, limited data exist on their impact on surgical outcomes, particularly during laparoscopic myomectomy. This case series describes the surgical findings in three patients who received preoperative Relugolix combination therapy (Relugolix-CT: relugolix-estradiol-norethisterone acetate) compared to no pretreatment. MATERIALS AND
methodsWe conducted a retrospective review of 24 patients who underwent laparoscopic myomectomy over a 6-month period. Three patients received a preoperative course of Relugolix-CT for 3, 6, and 9 months, respectively, while 21 patients underwent surgery without pretreatment.
resultsBlood loss was lower in the Relugolix-CT group (216.6 mL ± 189.7) vs. the no-pretreatment group (354.8 mL ± 131.9. Operating time was similar (148.3 vs. 148.1 min), as was duration of inpatient stay (1.3 vs. 2.0 days). No complications occurred in either group. Notably, in all cases with Relugolix-CT pretreatment, no distortion or fibrosis of the fibroid pseudocapsule was noted, allowing for complete resection of the fibroids.
conclusionsThis case series suggests that preoperative Relugolix-CT does not adversely affect surgical planes or operative outcomes. Although preliminary, these findings suggest benefits for surgical optimisation and support further investigation in larger, controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.